Buradasınız

Anasayfa » Content

Kronik Miyeloid Lökemi’ye Eşlik Eden Skuamoz Hücreli Karsinom: Olgu Sunumu ve Literatür Taraması

Squamous Cell Carcinoma Accompanying Chronic Myeloid Leukemia: Case Report and Review of the Literature

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2012

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Background: Chronic Myelogenous Leukemia (CML) is a myeloproliferative disorder characterized by, overproduction of myeloid cells. Hydroxyurea is an antimetabolite which is commonly used in myeloproliferative syndromes. Reported skin changes related to hydroxyurea therapy may range form xerosis to mucocutaneous cancers. Aim: In this study, our aim was to understand and discuss the underlying reason for the development of squamous cell carcinoma (SCC) in patients recieving hydroxyurea and present a case, in whomwe operated to excise the tumoral masses and reconstruct them. Materials and Methods: After recieving hydroxyuea therapy for four years, the patient was diagnosed as squamous cell carcinoma on the upper lip and, on the dorsum of the left hand. She was operated and the tumoral masses were excised. The lesion on the upper lip was reconstructed with nasolabial flap, inner and inferior sides of the flap was skin grafted. The defect on the dorsum of the hand was skin grafted. Results: No complication related to operation occured. Throughout postoperative eight months of follow-up period, the patient had no complaint regarding the operation. Conclusıon: Skin lesions of patients recieving hydroxyurea therapy must be carefully examined and monitored regularly, since these lesions may proceed to skin cancers.
Bookmark/Search this post with
Abstract (Original Language): 
Giriş: Kronik Miyeloid Lösemi (KML), miyeloid hücrelerin aşırı üretimi ile karakterize miyeloproliferatif bir hastalıktır. Hidroksiüre de miyeloproliferatif sendromlarda sıklıkla kullanılan bir antimetabilolit ilaçtır. Hidroksiüre tedavisine bağlı olarak bildirilen cilt değişiklikleri kserozizsten mukokutanöz kanserlere kadar çeşitlilik gösterir. Amaç: Bu çalışmada amacımız, hidroksiüre tedavisi alan hastalarda skuamoz hücreli karsinom gelişiminin altta yatan sebeplerini anlamak, tartışmak ve tümör eksizyonu ve rekonstruksiyonu yaptığımız böyle bir hastayı sunmaktır. Meteryal ve Metod: Üst dudak ve sol el dorsumunda skuamoz hücreli karsinom tanısı almış olan hasta dört yıldır hidroksiüre tedavisi almaktaymış. Bu hasta opere edilerek tümöral kitleleri eksize edildi ve üst dudakta oluşan defekt iç ve alt tarafları greftlenen nazolabial flep ile rekonstrukte edildi. El dorsumunda oluşan defekt ise cilt grefti ile kapatıldı. Bulgular: Yapılan operasyona bağlı bir komplikasyon ile karşılaşılmadı. Postoperatif sekiz aylık takip döneminde hastanın operasyona bağlı bir şikayeti olmadı. Sonuç: Hidroksiüre tedavisi alan hastaların cilt lezyonları cilt kanserine ilerleyebileceğinden dolayı dikkatli bir şekilde muayene edilmeli ve düzenli olarak takip edilmelidir.
FULL TEXT (PDF): 
PDF icon arastirmax-kronik-miyeloid-lokemiye-eslik-eden-skuamoz-hucreli-karsinom-olgu-sunumu-literatur-taramasi.pdf
  • 1
40-45
  • Turkish

REFERENCES

References: 

1. Bolin RW, Robinson WA, Sutherland J, et al. Busulfan
Versus Hydroxyurea in the Long-term Therapy of
Chronic Myelogenous Leukemia. Cancer 1982; 50: 1683-
6. DOI: 10.1002/1097-0142(19821101)50:9<1683::AIDCNCR2820500904>
3.0.CO;2-X
2. Kennedy BS, Smith LR, Goltz RW. Skin Changes
Secondary to Hydroxyurea Therapy. Arch Dermatol 1975;
11: 183-7. DOI: 10.1001/archderm.1975.01630140041002
3. Gropper CA, Don PC, Sadjadi MM. Nail and Skin
Pigmentation Associated with Hydroxyurea Therapy for
Polycythemia Vera. Int J Dermatol 1993; 32: 731-3. DOI:
10.1111/j.1365-4362.1993.tb02745.x
4. Nguyen TV, Margolis DJ. Hydroxyurea and Lower Leg
Ulcers. Cutis 1993; 52: 217-9.
5. Sigal M, Crickx B, Blanchet P, et al. Lesions Cutanees
Squamous Cell Carcinoma Accompanying Chronic Myeloid Leukemia: Case Report and Review of the
Literature
45
Induites par L’utilisation au Long Cours de L’hydroxyurea
en Chronic Myelogenous Leukemia. Ann Dermatol
Venereol 1984; 111: 895-900.
6. Richard M, Truchetet F, Friedel J, et al. Skin Lesions
Simulating Dermatomyositis During Long-term
Hydroxyurea Therapy. J Am Acad Dermatol 1989; 21:
797-9. DOI: 10.1016/S0190-9622(89)80274-9
7. Weber LL, Schick E, Merkel M, et al. Dermatomyositis-
Like Skin Changes with Long Term Hydroxyurea (Litalir)
Therapy. Hautartz 1995; 46: 717-21. DOI:
10.1007/s001050050328
8. Dadoud MS, Gibson LE, Pittelkow MR. Hydroxyurea
Induced Dermopathy: A Unique Lichenoid Eruption
Complicating Long Term Therapy with Hydroxyurea. J
Am Acad Dermatol 1997; 36: 178-82. DOI:
10.1016/S0190-9622(97)70276-7
9. Papi M, Didona B, De Pita O, et al. Multiple Skin Tumors
on Light Exposed Areas During Long-term Treatment
with Hydroxyurea. J Am Acad Dermatol 1993; 28: 485-6.
DOI: 10.1016/S0190-9622(08)81758-6
10. Grange F, Coulliet D, Audhuy B, et al. Keratoses
Multiples Induites par L’hydroxyuree. Ann Dermatol
Venereol 1995; 122: 16-8.
11. Linker CA. Blood, chronic myelogenous leukemia. In:
Tierney LM, McPhee SJ, Papadakis MA, editors. Current
Medical Diagnosis and Treatment. 41st ed. Mc Graw Hill;
2002. pp539-41.
12. Albano EA, Stork LC, Greffe BS, Odom LF, Foreman N.
Neoplastic disease, chronic myelogenous leukemia. In:
Hay WW, Groothuis JR, Hayward AR, Levin MJ, ed(s).
Current Pediatric Diagnosis and Treatment. 13th ed.
Appleton & Lange; 1997: 785.
13. Yarbro JB. Further Studies on the Mechanism of Action
of Hydroxyurea. Cancer Res 1968; 28: 1082-7.
14. Zu-An Y, Xinzhi L, Xianting Z. The Effect of
Hydroxyurea on the Expression of the Common Fragile
Site 3p14. J Med Genet 1987; 24: 593-6. DOI:
10.1136/jmg.24.10.593
15. Best PJ, Petitt RM. Multiple Skin Cancers Associated with
Hydroxyurea Therapy. Mayo Clin Proc 1998; 73: 961-3.
DOI: 10.4065/73.10.961
16. Klem EB. Effect of Antipsoriasis Drugs and Metabolic
Inhibitors on the Growth of Epidermal Cells in Culture. J
Invest Dermatol 1978; 9: 27-32. DOI: 10.1111/1523-
1747.ep12543421
17. Francis AA, Blevins RD, Carrier WL, et al. Inhibition of
DNA Repair in Ultraviolet-irradiated Human Cells by
Hydroxyurea. Biochem Biophys Acta 1979; 563: 385-92.
18. Angeli-Besson C, Koeppel MC, Jacquet P, et al. Multiple
Squamous Cell Carcinomas of the Scalp and Chronic
Leukemia. Dermatology 1995; 191: 321-2. DOI:
10.1159/000246586
19. Aste N, Fumo G, Biggio P. Multiple Squamous
Epitheliomas During Long-term Treatment with
Hydroxyurea. J Eur Acad Dermatol Venerol 2001; 15: 89-
90. DOI: 10.1046/j.1468-3083.2001.00200-11.x
20. Chang WC, Fujimiya Y, Casteel N, Pattengale P. Natural
Killer Cell Immunodeficiency in Patient with Chronic
Myelogenous Leukemia. Dermatologica 1991; 183: 47-8.
21. Vasallo C, Passamonti F, Merante S, et al.
Mucocuataneous Changes During Long-term Therapy
with Hydroxyurea in Chronic Myeloid Leukaemia. Clin
Exp Dermatol 2001; 26: 141-8. DOI: 10.1046/j.1365-
2230.2001.00782.x
22. Benedittis MDe, Petruzzi M, Giardina C, et al. Oral
Squamous Cell Carcinoma During Long-term Treatment
with Hydroxyurea. Clinical and Experimental
Dermatology 2004; 29: 605-7. DOI: 10.1111/j.1365-
2230.2004.01586.x
23. Esteve E, Georgescu V, Heitzmann P, Martin L. Multiple
Skin and Mouth Squamous Cell Carcinomas Relate to
Long Term Treatment with Hydroxyurea. Ann Dermatol
Venereol 2001; 128: 919-21.
24. Guyatt GH, Sackett DL, Cook DJ. Users’ Guide to the
Medical Literature. II. How o Use an Article About
Therapy or Prevention. B. What are the Results and will
They Help Me in Caring Form My Patients? Evidence-
Based Medicine Working Group. JAMA 1994; 271: 59-63.
DOI: 10.1001/jama.1994.03510250075039

Thank you for copying data from http://www.arastirmax.com